Bringing together the conflicting results of in vitro and clinical studies, it could be suggested that the only partial recovery of CFTR function recorded in patients lead to an improvement of clinical symptoms enabling the patient to tackle potential infections more effectively, but it does not directly affect in vitro SARS-CoV-2 replication capability that might depend also on other biochemical mechanisms associated to the CF phenotype. Here, CFTR is linked to cystic fibrosis.